Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 30 Jan 2022 | |
Solid tumor | Discovery | CN | - |